Clinical Trial Update: Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study of SKY-0515 for Huntington's disease is currently recruiting to evaluate pharmacodynamics, safety, and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• SKY-0515

Snippet

Sponsor: Skyhawk Therapeutics, Inc. | Conditions: Huntington Disease | Phase 2, Phase 3 | Status: RECRUITING